title: Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease.
abstract: Eighteen patients with active Crohn's disease were treated with one leukocytapheresis session per week for a five-week intensive therapy, decreasing to one leukocytapheresis session per month for five sessions of initial maintenance therapy. Nutritional indices, inflammatory reactions, flow cytometry profiles, and cytokine production were also assessed before and after the intensive and initial maintenance therapy. Nine of the patients (50%) attained remission at the end of the intensive therapy. The nine non-remission patients had exhibited longer periods of suffering and more severely affected sites prior to the therapy. In 14 of 18 patients (77.8%), the nutritional indices, Internal Organization of Inflammatory Bowel Disease (IOIBD) score and Crohn's Disease Activity Index (CDAI) improved from the pretherapy levels, but only the remission group (50%) showed improvement in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). The remission group showed significantly higher pretherapy CD4+ CD45+ cell ratios and interleukin-2 (IL-2) production than the non-remission group, and significantly lower activated cells.
authors.affiliation: Department of Internal Medicine IV, Hyogo College of Medicine, Nishinomiya.
authors.forename: T
authors.initials: T
authors.lastname: Kosaka
authors.forename: K
authors.initials: K
authors.lastname: Sawada
authors.forename: K
authors.initials: K
authors.lastname: Ohnishi
authors.forename: A
authors.initials: A
authors.lastname: Egashira
authors.forename: M
authors.initials: M
authors.lastname: Yamamura
authors.forename: N
authors.initials: N
authors.lastname: Tanida
authors.forename: M
authors.initials: M
authors.lastname: Satomi
authors.forename: T
authors.initials: T
authors.lastname: Shimoyama
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003424:Crohn Disease / Q000097:blood / Q000473:pathology / Q000628:therapy*; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007376:Interleukin-2 / Q000097:blood; D007937:Leukapheresis / Q000295:instrumentation / Q000379:methods*; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D008851:Micropore Filters; D009752:Nutritional Status; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006684:HLA-DR Antigens; D007376:Interleukin-2; D002097:C-Reactive Protein; D017493:Leukocyte Common Antigens